Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KOD Kodiak Sciences Inc.

Not Yet Opened 03-26 16:00:00 EDT

39.76

+17.01

+74.77%

盘后40.01

+0.25+0.63%

19:59 EDT

High40.46	Low33.50	Vol13.18M
Open35.41	D1 Closing22.75	Amplitude30.61%
Mkt Cap2.46B	Tradable Cap1.47B	Total Shares61.76M
T/O482.15M	T/O Rate35.75%	Tradable Shares36.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":39.76,"timestamp":1774555200000,"preClose":22.75,"halted":0,"volume":13184295,"hourTrading":{"tag":"盘后","latestPrice":40.01,"preClose":39.76,"latestTime":"19:59 EDT","volume":143253,"amount":5798629.0958,"timestamp":1774569591547,"change":0.25,"changeRate":0.006288,"amplitude":0.056119},"delay":0,"changeRate":0.7476923076923077,"floatShares":36879500,"shares":61758500,"eps":-4.119388,"marketStatus":"Not Yet Opened","change":17.01,"latestTime":"03-26 16:00:00 EDT","open":35.41,"high":40.4637,"low":33.5,"amount":482151909.48015,"amplitude":0.306097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.119388,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774598400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":22.75,"preHourTrading":{"tag":"盘前","latestPrice":35.7389,"preClose":22.75,"latestTime":"09:29 EDT","volume":895356,"amount":30024760.661280002,"timestamp":1774531798580,"change":12.9889,"changeRate":0.570941,"amplitude":0.682198},"postHourTrading":{"tag":"盘后","latestPrice":40.01,"preClose":39.76,"latestTime":"19:59 EDT","volume":143253,"amount":5798629.0958,"timestamp":1774569591547,"change":0.25,"changeRate":0.006288,"amplitude":0.056119},"volumeRatio":13.445605,"impliedVol":1.0457,"impliedVolPercentile":0.428},"requestUrl":"/m/hq/s/KOD","defaultTab":"news","newsList":[{"id":"2622123368","title":"Kodiak Sciences Inc : Jefferies Raises Target Price to $56 From $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2622123368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622123368?lang=en_us&edition=fundamental","pubTime":"2026-03-27 12:54","pubTimestamp":1774587271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40E0VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KOD","BK4505"],"gpt_icon":0},{"id":"2622341815","title":"Meta, Kodiak Sciences, Unity Software, Lumentum Holdings And Reddit: Why These 5 Stocks Are On Investors' Radars Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2622341815","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622341815?lang=en_us&edition=fundamental","pubTime":"2026-03-27 09:21","pubTimestamp":1774574460,"startTime":"0","endTime":"0","summary":"Major U.S. indices closed lower, with the Dow Jones Industrial Average declining 1.01% to 45,960.11.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/26/Financial-Graph-With-Uptrend-Line-Techno_3.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/26/Financial-Graph-With-Uptrend-Line-Techno_3.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/26/03/51500039/meta-kodiak-sciences-unity-software-lumentum-holdings-and-reddit-why-these-5-stocks-are-on-investors-radars-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/03/51500039/meta-kodiak-sciences-unity-software-lumentum-holdings-and-reddit-why-these-5-stocks-are-on-investors-radars-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0205193047.USD","LU1861220033.SGD","BK4020","U","RDDT","LU0012050646.USD","RDTL","LU0289739343.SGD","META","LU1861215975.USD","LU2290526834.HKD","LU0240877869.USD","BK4023","LU1861558580.USD","LU0511384066.AUD","LU0106261612.USD","LITE","LU2360107168.USD","BK4585","BK4077","LU0289961442.SGD","LU0205194284.USD","BK4588","UNX","RDYY","BK4547","BK4554","LU0240878834.USD","LU1861559042.SGD","BK4211","KOD"],"gpt_icon":1},{"id":"2622933568","title":"Kodiak Sciences Up Over 74%, on Pace for Record Percent Increase -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2622933568","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622933568?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:28","pubTimestamp":1774549680,"startTime":"0","endTime":"0","summary":"Kodiak Sciences, Inc.  is currently at $39.71, up $16.96 or 74.55%. --Would be highest close since Feb. 22, 2022, when it closed at $50.35. --Currently up two consecutive days; up 81.74% over this period. --Up 48.17% month-to-date; on pace for best month since Sept. 2025, when it rose 81.08%. --Down 75.86% from its all-time closing high of $164.47 on Jan. 19, 2021. --Up 1197.71% from 52 weeks ago , when it closed at $3.06. --Up 1827.67% from its 52-week closing low of $2.06 on April 8, 2025. --Traded as high as $40.46; highest intraday level since Feb. 22, 2022, when it hit $53.60. --Up 77.86% at today's intraday high; largest intraday percent increase since Dec. 2, 2019, when it rose as much as 146.53%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"gpt_icon":0},{"id":"2622898068","title":"Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898068?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:20","pubTimestamp":1774549219,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wave Life Sciences (WVE) and Kodiak Sciences (KOD) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-wave-life-sciences-wve-and-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-wave-life-sciences-wve-and-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4585","WVE","KOD","LU0128526141.USD","XLV","BK4007","BK4581","BK4137","LABU","XBI","BK4588","LU0029874061.USD","HCSG","BK4139"],"gpt_icon":0},{"id":"2622898033","title":"Kodiak Sciences price target raised to $56 from $39 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898033?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:10","pubTimestamp":1774548655,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Kodiak Sciences (KOD) to $56 from $39 and keeps a Buy rating on the shares. Following strong GLOW2 resu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-price-target-raised-to-56-from-39-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-price-target-raised-to-56-from-39-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOD","BK4139","BK4505"],"gpt_icon":0},{"id":"2622863672","title":"BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622863672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622863672?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:26","pubTimestamp":1774531560,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL6N40E0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QCMU","DBI","FCXG","GOU","UNFI","GNRC","HOOD","GOOY","HL","GGLL","LOVE","NEMG","ROBN","CMC","CBUS","NEM","HOII","CRBG","JEF","CDE","HODU","RIO.AU","HOOG","HLXX","NAVN","GOOW","HOYY","AIFF","FCX","GOOP","KOD","SCCO","HOOW","BK4538","QCMD","HOOZ","HOOX","BHP.AU","OLPX","HOOI","GOOX","HUBG","RIO.UK","NWMX","GGLS","QCML","WVE","HOOY"],"gpt_icon":1},{"id":"2622682698","title":"Wall Street Digests Fading Middle East Peace Prospects as US Equity Futures Decline Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2622682698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622682698?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:08","pubTimestamp":1774530535,"startTime":"0","endTime":"0","summary":"US equity futures were down ahead of Thursday's opening bell as traders monitored the latest developments in the Middle East.Dow Jones Industrial Average futures were 0.8% lower, S&P 500 futures were ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e37308e5c53d900cae7eac36e2e76cfa","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QQQE","QQQY","NAVN","DGRW","SPXU","DBSC","FTEC","NQmain","SPDN","DXD","MLKN","MOAT","SQQQ","QDTE","DIA","VOO","IYW","KOD","BMAY","RSP","QLD","YMAX","QID","GRNY","DJX","DDM","SPY","PSQ","EQR","MGK","QQQJ","SDOW",".IXIC","SPMO","QYLG","MNQmain",".DJI","SSO","VTI","SDS","XDTE","ALLW","SPYD","SPLV","SPYG",".SPX","DOG","SPHQ","IVW"],"gpt_icon":1},{"id":"2622545098","title":"Kodiak Sciences Shares Surge 40% Premarket After Eye Drug Succeeds in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2622545098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622545098?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:29","pubTimestamp":1774524568,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL4N40E0U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KOD","BK4505","BK4139"],"gpt_icon":0},{"id":"2622854313","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854313","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854313?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:23","pubTimestamp":1774524192,"startTime":"0","endTime":"0","summary":"Kodiak Sciences  shares were 38% higher pre-bell Thursday after the company said that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.Navan  stock was up 24%, a day after the company reported it swung to fiscal Q4 earnings amid higher revenue.Noodles  shares were 19% higher after the company reported late Wednesday improved Q4 financial results.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","BK4139","NAVN","NDLS","BK4209","BK4505","KOD"],"gpt_icon":0},{"id":"2622190851","title":"Kodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622190851","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622190851?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:08","pubTimestamp":1774523339,"startTime":"0","endTime":"0","summary":"Kodiak Sciences  said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.Ba","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KOD","BK4505"],"gpt_icon":0},{"id":"2622859254","title":"Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622859254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622859254?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:55","pubTimestamp":1774522500,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina.The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year.The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients.Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said.Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KOD","SSI","BK4139"],"gpt_icon":0},{"id":"2622285546","title":"Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285546","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285546?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:02","pubTimestamp":1774519369,"startTime":"0","endTime":"0","summary":"Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham. Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda  versus sham in diabetic retinopathy.The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham .In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham .Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate .Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL298zY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4505","BK4139"],"gpt_icon":0},{"id":"2622855168","title":"Kodiak Sciences Inc: Zenkuda Also Demonstrated Superiority to Sham With an 85% Risk Reduction in Key Secondary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855168?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:00","pubTimestamp":1774519242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0CK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KOD"],"gpt_icon":0},{"id":"2622554838","title":"Kodiak Sciences Inc: We Intend to Accelerate Our Bla Submission Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2622554838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622554838?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:00","pubTimestamp":1774519242,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0CK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KOD","BK4505"],"gpt_icon":0},{"id":"2622551548","title":"Kodiak: Zenkuda Demonstrated Favorable Safety,Well Tolerated in Study With 0% Intraocular Inflammation Rate and 2.3% Cataract Adverse Event Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622551548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622551548?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:00","pubTimestamp":1774519242,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0CK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2622157855","title":"Kodiak Sciences Inc: Zenkuda Demonstrated Strong Efficacy Independent of Concomitant Glp-1 Receptor Agonist Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2622157855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622157855?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:00","pubTimestamp":1774519242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0CK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KOD","BK4139"],"gpt_icon":0},{"id":"2622085596","title":"Kodiak Sciences Announces Positive Topline Results in Glow2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (Tarcocimab Tedromer) Over Sham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085596?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:00","pubTimestamp":1774519242,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","FEMY","KALV","CMC","MKC","CGNT","EQ","HYPD","AGX","HUMA","JEF","EPAC","BYND","BIRD","NKE","CCL","DOO","AURA","RNXT","BAK","CHWY","IKT","IMNN","BCAX","ABOS","BTGO","JBS","IMDX","CELC","CTAS","FDS","CNTX","GOVX","EDAP","KOD","BHST","AIRO","AIRJ","CNTB","DERM","FUL","BNZI","JILL","CDLR","DMAC","AUTL","BITF","DEFT","CNTA"],"gpt_icon":1},{"id":"2621814720","title":"Kodiak Sciences Inc  expected to post a loss of $1.03 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621814720","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621814720?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:06","pubTimestamp":1774296370,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc  expected to post a loss of $1.03 a share - Earnings Preview Kodiak Sciences Inc KOD.OQ KOD.O is expected to  show no change in quarterly revenue when it reports  results on March ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B2BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2620782840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782840?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:00","pubTimestamp":1774000800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRMN","EVTL","CNTA","ALMS","CMC","BZAI","ACHV","FUFU","BAK","FEMY","GUTS","CTAS","ABSI","BCAX","KBH","CHWY","AIR","DERM","DOO","CNTB","JBS","MXCT","EDAP","JEF","FENC","FUL","HSAI","GOVX","HUMA","CNXC","BTGO","CUK","ABVX","EPAC","CGNT","CELC","FBRX","AGX","KALV","IMNN","AVTX","EQ","CNTX","CNM","KOD","BRZE","HYPD","BYND","IKT"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.kodiak.com","stockEarnings":[{"period":"1week","weight":0.7542},{"period":"1month","weight":0.421},{"period":"3month","weight":0.3302},{"period":"6month","weight":1.5165},{"period":"1year","weight":12.2093},{"period":"ytd","weight":0.422}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.076525},{"month":2,"riseRate":0.5,"avgChangeRate":-0.093763},{"month":3,"riseRate":0.125,"avgChangeRate":-0.06924},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.000503},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076422},{"month":6,"riseRate":0.714286,"avgChangeRate":0.026986},{"month":7,"riseRate":0.571429,"avgChangeRate":0.078061},{"month":8,"riseRate":0.571429,"avgChangeRate":0.018756},{"month":9,"riseRate":0.714286,"avgChangeRate":0.127765},{"month":10,"riseRate":0.714286,"avgChangeRate":0.212883},{"month":11,"riseRate":0.75,"avgChangeRate":0.296496},{"month":12,"riseRate":0.625,"avgChangeRate":0.266402}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}